zastaprazan + apixaban

JP-1366 + apixaban is a drug combination consisting of zastaprazan (JP-1366) and apixaban. Zastaprazan is a novel, orally active potassium-competitive acid blocker (P-CAB) developed by Onconic Therapeutics (a subsidiary of Jeil Pharmaceutical) for the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD) and gastric ulcers. It works by competitively and reversibly inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells. Apixaban is a potent, oral, reversible, direct, and highly selective inhibitor of Factor Xa, used as an anticoagulant to prevent and treat thromboembolic events. The combination is being evaluated in Phase 1 drug-drug interaction (DDI) studies to assess the safety and pharmacokinetic profile of both agents when co-administered, ensuring that the acid-suppressing effects of zastaprazan do not adversely impact the therapeutic levels of apixaban.

Other names

JP-1366 + apixaban